Moleculin Biotech (MBRX) Liabilities and Shareholders Equity (2015 - 2026)
Moleculin Biotech (MBRX) posted quarterly Liabilities and Shareholders Equity of $22.1 million for Q4 2025, up 30.73% year-over-year from $16.9 million in Q4 2024, and up 8.71% quarter-over-quarter from $20.4 million in Q3 2025.
Moleculin Biotech (MBRX) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends
Moleculin Biotech's Liabilities and Shareholders Equity history runs 11 years deep, the most recent figure standing at $22.1 million for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity rose 30.73% year-over-year to $22.1 million; the TTM figure through Dec 2025 stood at $85.1 million (down 12.05% YoY), while the FY2025 annual figure was $22.1 million, up 30.73% from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 stood at $22.1 million, up from $20.4 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $99.8 million in Q1 2021, with the low at $16.9 million in Q4 2024.
- The 5-year median for Liabilities and Shareholders Equity is $43.3 million (2023), against an average of $49.9 million.
- The sharpest annual moves came in 2021 and 2024: Liabilities and Shareholders Equity surged 291.74% in 2021, then slumped 55.71% in 2024.
- Moleculin Biotech's Liabilities and Shareholders Equity stood at $84.1 million in 2021, then tumbled by 31.71% to $57.4 million in 2022, then sank by 33.45% to $38.2 million in 2023, then slumped by 55.71% to $16.9 million in 2024, then soared by 30.73% to $22.1 million in 2025.
- Business Quant data shows MBRX's Liabilities and Shareholders Equity at $22.1 million in Q4 2025, $20.4 million in Q3 2025, and $21.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - | 21.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.09 Mn |
| Dec 31, 2025 | 22.13 Mn |
| Sep 30, 2025 | 20.35 Mn |
| Jun 30, 2025 | 21.59 Mn |
| Mar 31, 2025 | 21.01 Mn |
| Dec 31, 2024 | 16.93 Mn |
| Sep 30, 2024 | 23.39 Mn |
| Jun 30, 2024 | 25.58 Mn |
| Mar 31, 2024 | 30.85 Mn |
| Dec 31, 2023 | 38.22 Mn |
| Sep 30, 2023 | 39.52 Mn |
| Jun 30, 2023 | 47.12 Mn |
| Mar 31, 2023 | 51.06 Mn |
| Dec 31, 2022 | 57.42 Mn |
| Sep 30, 2022 | 65.37 Mn |
| Jun 30, 2022 | 73.26 Mn |
| Mar 31, 2022 | 78.80 Mn |
| Dec 31, 2021 | 84.09 Mn |
| Sep 30, 2021 | 88.70 Mn |
| Jun 30, 2021 | 93.53 Mn |